secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001628280-23-000725
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics announces 2023 priorities, Phase 1 data expected in 2H 2023 for CFT7455 and CFT8634
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $366M as of Sep 30, 2022; expected to fund operations to end of 2024.
- Phase 1/2 trial of CFT7455 (IKZF1/3 degrader for multiple myeloma) continues; Phase 1 dose escalation data expected in 2H 2023.
- Phase 1/2 trial of CFT8634 (BRD9 degrader for synovial sarcoma) continues; Phase 1 data expected in 2H 2023; PK/PD data supportive of proof of mechanism.
- Phase 1/2 trial of CFT1946 (BRAF-V600 degrader for solid tumors) initiated; IND submission for CFT8919 (EGFR L858R NSCLC) planned in 1H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023000725/0001628280-23-000725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023000725/cccc-20230109.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-000725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer